Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1BT----[3] 96, 97, 98
2BT-11----[2] 96, 97
3BT-11 (1000 mg)----[1] 97
4BT-11 (500 mg)----[1] 97
5BT-11 (Omilancor)----[1] 96
6BT-11 1,000 mg----[1] 96
7BT-11 1000mg----[3] 96, 97, 98
8BT-11 500 mg----[2] 96, 97
9BT-11 500mg----[1] 98
10BT-11 Active----[2] 96, 97
11BT051 200 mg----[1] 97
12BT051 3200 mg----[1] 97
13BT051 800 mg----[1] 97
14BT061----[1] 46
15BT061 (CD4 monoclonal antibody)----[1] 46
16BT063----[1] 49
17BT090----[1] 65
18BT524----[1] 65
19BT595----[2] 63, 65
20BT681----[1] 65
21BT971----[1] 46
22BTK Inhibitor----[3] 46, 53, 160
23BTRX-246040[1] BTRX-246040---[1] 6
24BTT-1023----[1] 46
25BTT1023----[1] 94
26BTT1023 IV Infusion 20 mg/mL, 5 mL Drug Product----[1] 94
27BTX-A[1] Botulinum toxin type A (Synonym: BTX-A)[1] D00783 [1] SNAP25 💬[2] Insulin secretion, Synaptic vesicle cycle 💬[1] 6
28Bupivacaine, triamcinolone, and heparin (BTH)[3] Bupivacaine,
Heparin,
Triamcinolone		[3] D00385 ,
D07510 ,
D07552 		[7] NR3C1,
SCN1A,
SCN2A,
SCN3A,
SCN5A,
SCN9A,
SERPINC1 💬		[5] Adrenergic signaling in cardiomyocytes, Complement and coagulation cascades, Dopaminergic synapse, Neuroactive ligand-receptor interaction, Taste transduction 💬[1] 226
29Dysport® (Botulinumtoxin A (Btx A))[1] Botulinum toxin type A (Synonym: BTX-A)[1] D00783 [1] SNAP25 💬[2] Insulin secretion, Synaptic vesicle cycle 💬[1] 36
30IgG Next Generation (BT595)----[1] 65
31Plasma rico en plaquetas y coagulo de fibrina procesados mediante la tecnología PRGF-System (BTI)----[1] 96